medigraphic.com
ISSN 2007-3178 (Print)
Asociación Mexicana de Cirugía Bucal y Maxilofacial, Colegio Mexicano de Cirugía Bucal y Maxilofacial, A.C.

2026, Number 1

<< Back Next >>

Rev Mex Cir Bucal Maxilofac 2026; 22 (1)

Extranodal nasal T/NK cell lymphoma. Clinical case presentation

Ibarra GF, Carrillo RJA, González BJ, García GJÁ, Fuentes SA, Espinosa BRV, Aguirre ME, Pastor FA, López CR, Guillén ZD

Language: Spanish
References: 16
Page: 21-25
PDF size: 1574.50 Kb.


ABSTRACT

Introduction: extranodal nasal T/NK cell lymphoma was described as a lethal midline granuloma in 1994 and classified within the group of non-Hodgkin lymphomas. In 2022, the WHO included it in the group of angiocentric immunoproliferative lesions of post-thymic T cells with Epstein-Barr virus positivity, changing its name to extranodal nasal T/NK cell lymphoma. Its prevalence compared to all lymphoma types is 1.5 to 2.6%. Objective: to report a clinical case of extranodal nasal T/NK cell lymphoma, including its histological characteristics, treatment, and prognosis. Case report: a 43-year-old male presented with a destructive midfacial lesion affecting the nasal septum, turbinates, paranasal sinuses, tympanic region, and mastoid process. He had no systemic diseases and a history of surgical procedures and antibiotic regimens without satisfactory response. A tissue biopsy was performed on the palate and mastoid region with immunohistochemistry for cytotoxic markers (CD56+, CD3+) and in situ hybridization for EBER for small RNAs encoded by the Epstein-Barr virus. The diagnosis was confirmed based on its progressive and destructive angioinvasion. Conclusions: extranodal NK/T cell lymphoma is a rare, aggressive neoplasm characterized by an angiocentric granulomatous and angioinvasive infiltrate, which causes necrosis and generally has an aggressive course. Diagnosis is based on the duration of the disease and clinical characteristics, as well as paraclinical studies that should include serology, culture, biopsy, and immunohistochemistry. Treatment includes radiotherapy and adjuvant chemotherapy, depending on the extent of the disease and the patient’s condition.


REFERENCES

  1. Kim JE, Kim YA, Jeon YK, Park SS, Heo DS, Kim CW. Comparativeanalysis of NK/T-cell lymphoma and peripheral T-cell lymphoma inKorea: Clinicopathological correlations and analysis of EBV straintype and 30-bp deletion variant LMP1. Pathol Int. 2003; 53 (11):735-743.

  2. Valdez L, Andrade V, Nellen H, Halabe J. Síndrome destructivo dela línea media. Rev Fac Med UNAM. 2003; 46 (2): 59-62.

  3. Meneses-García A, Súchil-Bernal L, de la Garza-Salazar J, Gómez-González E. Linfomas angiocéntricos centrofaciales de células T/NK. Aspectos histopatológicos y algunas consideraciones clínicasde 30 pacientes del Instituto Nacional de Cancerología, México. CirCiruj. 2002; 70: 410-416.

  4. Torre-Iturraspe S, LlorenteJ.C, Rodríguez V et al. Linfoma nasal decélulas T/NK. Rev Esp Cir Oral y Maxilofac. 2005; 27: 100-108.

  5. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathologicalspectrum of CD8-positive cutaneous T-cell lymphomas. J CutanPathol. 2002; 29 (8): 465-472.

  6. Pagnoux C, Teixeira L. Granulomatose de Wegener [Wegener’sgranulomatosis]. Presse Med. 2007; 36 (5 Pt 2): 860-874.

  7. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, NolleB et al. An interdisciplinary approach to the care of patients withWegener’s granulomatosis: long-term outcome in 155 patients.Arthritis Rheum. 2000; 43 (5): 1021-1032.

  8. Bacon PA. The spectrum of Wegener’s granulomatosis anddisease relapse. N Engl J Med. 2005; 352 (4): 330-334.

  9. Benavides JMP, Ferreira CG, Cohen AR, Tobal CA, Rojas SR.Reporte de caso: linfoma extranodal de células T/NK tipo nasalen Costa Rica. Rev Cienc Salud Integr Conoc. 2023; 7. Disponibleen: https://revistacienciaysalud.ac.cr/ojs/index.php/cienciaysalud/article/view/649/766

  10. Harris NL, Jaffe ES, Diebold J et al. The World Health Organizationclassification of neoplasms of the hematopoietic and lymphoidtissues: report of the Clinical Advisory Committee meeting--AirlieHouse, Virginia, November, 1997. Hematol J. 2000; 1 (1): 53-66.

  11. Slater DN. The new World Health Organization Classification ofhaematopoietic and lymphoid tumours: a dermatopathologicalperspective. Br J Dermatol. 2002; 147 (4): 633-639.

  12. Carrillo RJ, Gil RG, García SM. Leucemia linfocítica crónica/Linfoma linfocítico de células pequeñas. Revista Mexicana deEstomatología. 2015; 1 (1): 2-8.

  13. Saavedra RJD. Linfoma nasal de células T/natural Killer extranodalrefractario mal diagnosticado, tratado de manera exitosa: informede caso. Case Rep Oncol. 2017; 10 (3): 1092-1097.

  14. Rodd AL, Ververis K, Karagiannis TC. Safety and efficacyof pralatrexate in the management of relapsed or refractoryperipheral T-cell lymphoma. Clin Med Insights Oncol. 2012; 6:305-314.

  15. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J et al. PhaseII trial of concurrent radiation and weekly cisplatin followedby VIPD chemotherapy in newly diagnosed, stage IE toIIE, nasal, extranodal NK/T-cell lymphoma: consortium forImproving Survival of Lymphoma study. J Clin Oncol. 2009;27: 6027-6032.

  16. Akram SM, Attia FN. Mycobacterium avium complex. 2023 Feb25. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2026 Jan–. Available in: https://www.ncbi.nlm.nih.gov/books/NBK431110/




2020     |     www.medigraphic.com